Nebivolol Sandoz

Nebivolol, the active ingredient in Nebivolol Sandoz, is a beta blocker presented as a tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Nebivolol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic receptor blocker used in the management of hypertension.

- Hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk in adults.

Common side effects are generally mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: especially on standing. - Fatigue: feeling of reduced energy. - Bradycardia: slower than normal heart rate. - Nasal congestion: blocked or runny nose. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: heart rate drops to dangerously low levels. - Atrioventricular block: impaired electrical conduction. - Bronchospasm: difficulty breathing, especially in asthmatic patients. - Allergic reactions: rash, itching, or swelling. - Hepatic injury: abnormal liver function tests. - Acute heart failure exacerbation: worsening of cardiac symptoms.

Before initiating therapy, clinicians should consider several safety aspects.

- Blood pressure monitoring: ensure adequate control and avoid hypotension. - Heart rate assessment: watch for excessive bradycardia. - Hepatic function: caution in severe liver impairment. - Asthma or chronic obstructive pulmonary disease: avoid in patients with bronchospastic disease. - Discontinuation: do not stop abruptly; taper under medical supervision. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol may interact with other medicines that affect heart rate, blood pressure, or its metabolism.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of severe bradycardia. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol plasma concentrations. - Anti‑arrhythmic agents (amiodarone): may cause profound conduction disturbances.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect. - Diuretics: can enhance hypotensive response. - ACE inhibitors or ARBs: additive blood pressure lowering. - Other antihypertensives: monitor for excessive hypotension.